Browse News
Filter News
Found 418 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
4/18/2024
Arbutus Biopharma Corporation , today announced that it has scheduled its first quarter 2024 financial results and corporate update for Thursday, May 2, 2024.
-
RNAi Therapeutics Market Size to Climb USD 4.28 Billion by 2033
4/17/2024
The RNAi therapeutics market size reached a value of USD 1.11 billion by 2023 is expected to surge USD 4.28 billion by 2033, projections indicate an impressive CAGR of 14.9% over the forecast period 2023 – 2033, a study by Towards Healthcare.
-
A Delaware judge on Wednesday agreed with Roivant subsidiary Arbutus and Genevant’s interpretation of specific patent claims regarding the lipid nanoparticle delivery system used by Moderna’s COVID-19 vaccine.
-
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
4/4/2024
Arbutus Biopharma Corporation today issued the following statement regarding the claim construction ruling of the U.S. District Court for the District of Delaware in the lawsuit brought by Arbutus and its licensee Genevant Sciences (Plaintiffs) against Moderna.
-
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
3/20/2024
Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, announced its financial results for the year ended December 31, 2023, and an overview of the Company’s progress.
-
Arbutus to Participate in Two Upcoming Investor Conferences - March 8, 2024
3/8/2024
Arbutus Biopharma Corporation today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL.
-
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
2/29/2024
Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”) today reports fourth quarter and year end 2023 financial results and provides a corporate update.
-
Longtime Gilead Commercial Executive Joins IntegriChain as Chairman of the Board
2/28/2024
IntegriChain announced the appointment of Jim Meyers, a highly experienced pharmaceutical commercialization executive, as Chairman of the Board.
-
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
2/15/2024
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, reported its consolidated financial results for the fourth quarter and full year ended December 31, 2023 and reviewed recent business highlights.
-
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
2/15/2024
Arbutus Biopharma Corporation announced that it has scheduled its fourth quarter and year end 2023 financial results and corporate update for Thursday, February 29, 2024.
-
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
1/8/2024
Arbutus Biopharma Corporation announced its 2024 business outlook including its clinical development milestones to advance its HBV pipeline and a financial update.
-
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
1/5/2024
Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today provided a preliminary financial update and announced its 2024 corporate objectives.
-
Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies
11/15/2023
Mural Oncology plc launched as an independent, publicly traded, clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers.
-
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®
11/10/2023
Assembly Biosciences, Inc. (Nasdaq: ASMB) today announced new data from its virology portfolio featured in two presentations at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®, taking place November 10-14, 2023, in Boston.
-
Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023
11/9/2023
Ascletis Pharma Inc. announces that Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held at Boston, United States.
-
Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
11/9/2023
Barinthus Biotherapeutics plc, formerly Vaccitech plc, announced its financial results for the third quarter of 2023 and provided an overview of its progress.
-
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
11/9/2023
Arbutus Biopharma Corporation (Nasdaq: ABUS) and Barinthus Biotherapeutics plc (Nasdaq: BRNS), formerly Vaccitech plc, a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer, today announced a late breaking poster presentation at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023.
-
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
11/9/2023
Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced the presentation of data from two HBV clinical trials at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023.
-
Arbutus to Present at Jefferies London Healthcare Conference - November 8, 2023
11/8/2023
Arbutus Biopharma Corporation today announced that the Arbutus management team will participate in and host one-on-one meetings at the following investor conference.